Estradiol valerate/methenmadinone caproate

Estradiol valerate /
methenmadinone caproate
Estradiol valerate (top) and
methenmadinone caproate (bottom)
Combination of
Estradiol valerateEstrogen
Methenmadinone caproateProgestogen
Clinical data
Other namesEV/MMC; Lutofollin
Routes of
administration		Intramuscular injection
Identifiers
CAS Number

Estradiol valerate/methenmadinone caproate (EV/MMC), known by the tentative brand name Lutofollin, is a combination medication of estradiol valerate (EV), an estrogen, and methenmadinone caproate (MMC; superlutin caproate), a progestin, which was developed for potential use as a once-a-month combined injectable contraceptive but was never marketed.[1][2][3] It contained 10 mg EV and 60 mg MMC in 1 mL oil solution and was intended for administration by intramuscular injection once every 4 weeks.[1][2][3]

See also

References

  1. 1 2 Stĕrba R (January 1976). "Tschechoslowakisches Injektionskontrazeptivum, einmal im Monat zu verabreichen" [A Czechoslovak injection-contraceptive agent administered once a month]. Zentralblatt für Gynakologie (in German). 98 (3): 158–160. ISSN 0044-4197. PMID 970015.
  2. 1 2 Mokhtar K. Toppozada (1983), Monthly Injectable Contraceptives
  3. 1 2 Toppozada MK (April 1994). "Existing once-a-month combined injectable contraceptives". Contraception. 49 (4): 293–301. doi:10.1016/0010-7824(94)90029-9. PMID 8013216.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.